PULMONARY EMBOLISM

โœ“ Medically ReviewedRESPIRATORYID: MDBTH005ICD-11: BB10๐Ÿšจ CRITICAL PROTOCOL
๐Ÿ’ก Core Clinical Guidance

Pulmonary embolism (PE) is the obstruction of one or more pulmonary arteries by thrombus (most commonly), air, fat, tumour, or amniotic fluid. In the vast majority of cases it originates from deep vein thrombosis (DVT) in the lower extremities or pelvis. PE causes impaired gas exchange, increased pulmonary vascular resistance, and potentially right ventricular failure.

๐Ÿ“–

Definition

CLINICAL DEFINITION & PATHOPHYSIOLOGY

Pulmonary embolism (PE) is the obstruction of one or more pulmonary arteries by thrombus (most commonly), air, fat, tumour, or amniotic fluid. In the vast majority of cases it originates from deep vein thrombosis (DVT) in the lower extremities or pelvis. PE causes impaired gas exchange, increased pulmonary vascular resistance, and potentially right ventricular failure.

๐Ÿ’Š

Pharmacological Management โ˜…

FIRST-LINE REGIMENS
10 mg twice daily (days 1โ€“7), then 5 mg twice dailyPOTwice daily3โ€“6 months minimum; consider extended therapy

DOAC (direct oral anticoagulant); first-line for PE in most patients; no monitoring required

๐Ÿ’Š Rivaroxaban

15 mg twice daily (days 1โ€“21), then 20 mg once daily with mealPOOnce daily (maintenance)3โ€“6 months minimum

Alternative DOAC; once-daily maintenance dose improves adherence

ALTERNATIVE & ESCALATION REGIMENS

๐Ÿ’Š LMWH (e.g., Enoxaparin) + Warfarin

Enoxaparin 1.5 mg/kg SC once daily; Warfarin 5โ€“10 mg loadingSC + POOnce daily (LMWH); once daily (Warfarin)Overlap 5 days until INR 2โ€“3 on 2 consecutive days; then Warfarin alone

Used in antiphospholipid syndrome (LMWH preferred), pregnancy (LMWH throughout), and where DOACs not available

ADJUNCTIVE & ADD-ON THERAPIES

๐Ÿ’Š Massive PE with haemodynamic instability: IV alteplase 100 mg over 2 hours (systemic thrombolysis)

๐Ÿ’Š Catheter-directed thrombolysis or surgical embolectomy if systemic thrombolysis contraindicated

๐Ÿ’Š IVC filter if anticoagulation absolutely contraindicated or recurrent PE despite anticoagulation

๐Ÿ’Š IV unfractionated heparin (UFH) in massive PE (acts immediately; reversible)

๐Ÿ’Š Vasopressors (noradrenaline) for haemodynamic support in massive PE

SPECIAL PATIENT POPULATIONS
PREGNANCY
  • LMWH (therapeutic dose) throughout pregnancy and โ‰ฅ3 months post-delivery
  • DOACs and warfarin contraindicated in pregnancy
GERIATRICS
  • DOACs preferred over warfarin
  • Higher bleeding risk: consider dose reduction
  • Assess fall risk before anticoagulation
PAEDIATRICS
  • LMWH or anticoagulation under specialist guidance
  • Investigate for underlying thrombophilia
RENAL IMPAIRMENT
  • Avoid DOACs if eGFR <25 mL/min
  • LMWH with anti-Xa monitoring if eGFR 15โ€“30
  • UFH if severe renal impairment
HEPATIC IMPAIRMENT
  • Avoid DOACs in significant hepatic impairment (coagulopathy risk)
  • LMWH preferred with monitoring
CONTRAINDICATIONS & SAFETY CAUTIONS
  • Apixaban/Rivaroxaban: avoid in severe renal failure (CrCl <15โ€“25 mL/min), severe hepatic impairment, pregnancy
  • Warfarin: multiple drug interactions; requires INR monitoring; avoid in first trimester
  • Thrombolysis: contraindicated in active bleeding, recent surgery/trauma, haemorrhagic stroke, absolute bleeding risk
  • LMWH: use with caution in severe renal impairment (monitor anti-Xa); avoid if eGFR <30 (use UFH)
โš–๏ธCLINICAL NOTICE & EDUCATIONAL DISCLAIMER

All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.